Multiple myeloma: Diagnosis and therapy

被引：0

作者：

H. Goldschmidt

F. W. Cremer

T. M. Möhler

A. D. Ho

机构：

[1] Medizinische Klinik und Poliklinik V, Universität Heidelberg, Heidelberg

[2] Medizinische Klinik und Poliklinik V, Universität Heidelberg, 69115 Heidelberg

来源：

Der Onkologe | 2003年 / 9卷 / 10期

关键词：

Bisphosphonates; High-dose therapy; Multiple myeloma; Stem cell transplantation; Thalidomide;

D O I：

10.1007/s00761-003-0592-0

中图分类号：

学科分类号：

摘要：

Multiple myeloma is one of the 20 most frequent malignancies in Germany. Initial symptoms are usually non-specific. Assessment of bone marrow and laboratory data as well as imaging techniques are essential for diagnosis and prognostic evaluation. Data from molecular cytogenetics have led to a better understanding of the pathogenesis of multiple myeloma. Cytostatic therapy with alcylating agents and glucocorticoids prolongs the survival. High-dose therapy followed by transplantation of autologous hematopoietic stem cells improves prognosis for patients up to the age of 70. Currently, modifications of allogeneic hematopoietic stem cell transplantation, anti-angiogeneic and immunomodulatory drugs as well as proteasome inhibitors are evaluated in clinical trials. Supportive care has derived benefit from the introduction of new bisphosphonates.

引用

页码：1152 / 1168

页数：16

共 20 条

[1]

Alexanian R., Dreicer R., Chemotherapy for multiple myeloma, Cancer, 53, pp. 583-588, (1984)

[2]

Barlogie B., Smith L., Alexanian R., Effective treatment of advanced multiple myeloma resistant to alkylating agents, N Engl J Med, 310, pp. 1353-1356, (1984)

[3]

Barlogie B., Jagannath S., Desikan K.R., Et al., Total therapy with tandem transplantation for newly diagnosed multiple myeloma, Blood, 93, pp. 55-65, (1999)

[4]

Bartl R., Frisch B., Bone marrow biopsy and aspiration for diagnosis of multiple myeloma, Myeloma: Biology and Management, 2nd Edn., pp. 89-121, (1998)

[5]

Dietzfelbinger H., Wick M., Bartl R., Lamerz R., Prognostische Faktoren, Manual Multiples Myelom - Empfehlungen zur Diagnostik, Therapie und Nachsorge, pp. 79-86, (2002)

[6]

Durie B.G.M., Salmon S.E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, 36, pp. 842-854, (1975)

[7]

Durie B.G.M., Staging and kinetics of multiple myeloma, Semin Oncol, 13, pp. 300-309, (1986)

[8]

Gahrton G., Svensson H., Cavo M., Et al., Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres, Br J Haematol, 113, pp. 209-216, (2001)

[9]

Goldschmidt H., Lannert H., Bommer J., Ho A.D., Multiple myeloma and renal failure, Nephrol Dial Transplant, 15, pp. 301-304, (2000)

[10]

Goldschmidt H., Cremer F.W., Das Multiple Myelom (Plasmozytom) - Diagnose und Therapie, (2002)

← 1 2 →